Double hit lymphoma in the northern region of England—A retrospective analysis of patient and disease characteristics, treatment delivered and survival

Le résumé fourni par la source

IPI) while 4 of them included patients with intermediate-high and high risk age-adjusted IPI.Regarding maintenance therapy, 7 trials included rituximab as the maintenance therapy, 3 included Interferon alfa as maintenance, 2 included immunomodulatory drugs (thalidomide and lenalidomide), one trial included cyclophosphamide and prednisone and one included the serine threonine kinase inhibitor enzastaurin.Data from 9 trials were available for analysis of OS.Maintenance treatment did not improve OS compared to observation, HR 0.98, 95% confidence interval (CI), 0.85-1.13,I 2 = 0. Results were the same in a subgroup analysis by the type of maintenance (rituximab vs other).Maintenance therapy did not decrease all-cause mortality at 1 year.However, it decreased relapse rate and improved disease control (HR 0.78, 95% CI, 0.65-0.93,I 2 = 52, random effects model and HR 0.74, 95% CI, 0.65-0.84,I 2 = 51, respectively).Disease control was significantly improved in the subgroup of studies evaluating rituximab as maintenance.Regarding safety, neutropenia and infections grade 3-4 were statistically significantly more common on the maintenance arm as compared to the observation arm.Conclusions: Maintenance therapy in patients with DLBCL achieving CR or PR after induction therapy did not affect OS, yet it decreased relapse rate and improved disease control at the cost of a higher infection rate.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.